Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Multiple Myeloma 10Neoplasms 8Lymphoma 7Carcinoma, Non-Small-Cell Lung 7Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms, Plasma Cell 4Advanced Solid Tumors 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Lung Neoplasms 3Leukemia 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Solid Tumors 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1

Interventions

Azacitidine 23fludarabine phosphate 17Cyclophosphamide 16Decitabine 12Cytarabine 11Peripheral Blood Stem Cell Transplantation 10Whole-Body Irradiation 9Mycophenolic Acid 9Filgrastim 8Tacrolimus 7Cyclosporine 7venetoclax 6decitabine and cedazuridine drug combination 6fludarabine 5Carboplatin 5sargramostim 4Vorinostat 4Specimen Handling 4Sirolimus 4Radiotherapy 4Injections 4Cyclosporins 4Clofarabine 4Busulfan 4ruxolitinib 3cedazuridine 3aldesleukin 3Topotecan 3Melphalan 3Leucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Chronic × Panobinostat × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01613976 2020-12-19

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Novartis

Phase 1 Completed
10 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡